期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉西他滨联合卡培他滨二线治疗晚期乳腺癌的疗效评价 被引量：10

在线阅读 下载PDF
导出
摘要 目的探讨吉西他滨联合卡培他滨二线治疗晚期乳腺癌的临床疗效。方法选取2011年6月至2013年6月收治的81例晚期转移性乳腺癌患者,采用吉西他滨联合卡培他滨化疗方案,观察其疗效及不良反应情况。结果 81例患者的无进展生存时间（progression free survival,PFS）为8.5个月。CR 6例（7.41%）,PR 30例（37.04%）,SD 32例（39.51%）,PD 13例（16.05%）,总有效率为44.45%。1年生存率为60.49%（49/81）,2年生存率为28.40%（23/81）。血液系统毒性（中性粒细胞减少、血红蛋白减少、血小板减少）主要为Ⅰ~Ⅱ度,Ⅲ度较少,未见Ⅳ度发生;其他不良反应如手足综合征、胃肠道反应及口腔黏膜损伤也仅限于Ⅰ、Ⅱ度,给予对症处理后均缓解。结论吉西他滨联合卡培他滨二线治疗晚期转移性乳腺癌效果显著,值得临床推广使用。
作者 文芳 翁洁 罗盘
机构地区 岳阳市一人民医院肿瘤科
出处 《中国肿瘤外科杂志》 CAS 2015年第3期184-185,188,共3页 Chinese Journal of Surgical Oncology
关键词 吉西他滨 卡培他滨 联合化疗 晚期乳腺癌
分类号 R737.9 [医药卫生—肿瘤]
作者简介 文芳，女，副主任医师，从事肿瘤内科的临床工作，E—mail：6479512@qq．com
  • 相关文献

参考文献14

  • 1郑向欣,管小青,吴骥,顾书成,袁牧,张旭旭.培美曲塞联合奈达铂治疗晚期乳腺癌的近期疗效[J].中国肿瘤外科杂志,2014,6(1):12-15. 被引量：9
  • 2蒋祥德,刘友如,施朕善.吉西他滨联合卡培他滨治疗复发转移性乳腺癌的临床观察[J].安徽医药,2014,18(2):335-336. 被引量：6
  • 3Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first- line therapy in patients with metastatic breast cancer: a phase 1I trial[J]. Oncology ,2002,62( 1 ) :2-8.
  • 4Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, Phase l] study of capecitabine in taxane-pretreated metastatic breast carci- noma patients [ J ]. Cancer, 2001,92 (7) : 1759-1768.
  • 5Benekli M,Yildiz R,Uner A,et al. Gemcitabine plus capecitabine com- bination in metastatic breast cancer patients previously treated with an- thracyclines and taxanes[J]. Oncology,2007,72(5-6) :308-313.
  • 6Heinemann V. Gemcitabine plus cisplatin for the treatment of meta- static breast cancer[ J 1. Ctin Breast Cancer, 2002,Suppl 1:24-29.
  • 7Mitsumori M, Hiraoka M, Okuno Y, et al. A phase I and II clini- cal trial of a newly developed ultrasound hyperthermia system with an improved planar transducer[ J]. Int J Radiat Oncol Biol Phys, 1996, 36(5) :1169-1175.
  • 8Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy assalvage chemotherapy in heavily pretreated metastatic breast cancer [ J ]. Breast Cancer Res Treat, 2005, 90 ( 3 ) :215-221.
  • 9Seidman AD. Monotherapy options in the management of meta- static breast cancer [ J ]. Semin Oncol, 2003, 30 ( 2 Suppl 3 ) : 6-10.
  • 10Heinemann V, Stemmler Hi, Wohlrab A, et al. High efficacy of gemcitabine and cisplatin in patients with predominantly anthra- cycline- and taxane-pretreated metastatic breast cancer [ J ]. Cancer Chemother Pharmacol, 2006, 57 (5) :640-646.

二级参考文献20

  • 1郝代钧,樊建淑,张海燕.吉西他滨联合卡培他滨二线治疗晚期乳腺癌[J].中国癌症杂志,2007,17(8):647-649. 被引量：8
  • 2Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CACancer J Clin,2010,60(5}:277-300.
  • 3Barnett CM.Survival data of patients with anthracycline or taxane-pretreated or resistant metastatic breast cancer[J].Pharmaco-ther-apy,2009,29(12):1482-1490.
  • 4Pallis AG,Boukovinas I,Ardavanis A,et,al.A multicenter ran-domized phase III trial of vinorelbine/gemcitabine doublet versuscapecitabine monotherapy in anthracycline-and taxane-pretreatedwomen with metastatic breast cancer[J].Ann Oncol,2012,23(5):1164-1169.
  • 5Ciruelos EM,Cortes J,Cortes-Funes H,et al.Gemcitabine andcapecitabine in previously anthracycline-treated metastatic breastcancer:a multicenter phase II study(SOLTI 0301 trial)[J].AnnOncol,2010,21(7):1442-1447.
  • 6Stemmier HJ,diGioia D,Freier W,et al.Randomised phase II trialof gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vsgemcitabine plus capecitabine in patients with pretreated metastat-ic breast cancer[J].Br J Cancer,2011,104(7):1071-1078.
  • 7Qi WX,Tang LN,He AN.Comparison between doublet agents ver-sus single agent in metastatic breast cancer patients previouslytreated with an anthracycline and a taxane:A meta-analysis of fourphase III trials[J].Breast,2013,22(3):314-319.
  • 8Martin M, Blasinska-Morawiec M, Salas JF, et al. A multi- center, single arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer [J]. Clin Breast Cancer, 2009, 9(3) :155-160.
  • 9Robert NJ, Conkling PR, Olourke MA, et al. Results of a phase 11 study of pemetrexed as first line chemotherapy in patients with advanced or metastatic breast cancer [ J ]. Breast Cancer Res Treat, 2011, 126(1 ) :101-108.
  • 10O' shaughnessy JA, Clark RS, Blum JL, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer [ J ], Clin Breast Cancer, 2005, 6 (2) : 143-149.

共引文献13

同被引文献115

  • 1张少华,江泽飞,宋三泰,申戈,王涛,曾敏,郭中宁.泰索帝联合希罗达治疗蒽环类化疗失败复发转移性乳腺癌的临床研究[J].癌症进展,2004,2(3):217-220. 被引量：59
  • 2中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量：271
  • 3Sandro Barni, Roberto Labianca, Giancarlo Agnelli, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect ofnadroparin thromboprophylaxis: Results of a retrospective analysis of thePROTECHT study[J]. J Transl Med, 2011, 9: 179.
  • 4Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxisand treatment in cancer: a consensus statement of major guidelines panels andcall to action[J]. J Clin Oncol, 2009, 27(29): 4919 - 4926.
  • 5Kamali F, Khan TI, King BP, et al. Contribution of age, body size, andCYP2C9 genotype to anticoagulant response to warfarin[J]. Clin PhamacolTher, 2004, 75: 204- 212.
  • 6Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 andVKORCl genetic polymorphign and patient characteristics upon warfarindose requirements: proposal for a new dosing regimen[J] . Bl o o d, 2005,106: 2329-2333.
  • 7Borson R, Harker G, Reeves J, et al. Phase lJ study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2- negative, locally recurrent or metastatic breast cancer. Clin Breast Cancer, 2012, 12(5): 322-330.
  • 8Mangini NS, Wesolowski R, Ramaswamy B, et al. Palbociclib: a novel cyclin-dependent kinase inhibitor for hormone receptor- positive advanced breast cancer. Ann Pharmacother, 2015, 49(11): 1252-1260.
  • 9Lawson DA, Bhakta NR, Kessenbrock K, et al. Single-cell analysis reveals a stem-ceU program in human metastatic breast cancer cells. Nature, 2015, 526(7571): 131-135.
  • 10Golubnitschaja O, Yeghiazaryan K, Costigliola V, et al. Risk assess- ment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon. EPMA J, 2013, 4(1): 6.

引证文献10

二级引证文献87

中国肿瘤外科杂志
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部